Table 1 Primary Characteristics of the Studies
Study (year) | Country | Perspective | Currency/year | Economic study type | Time horizon | Discount rate |
|---|---|---|---|---|---|---|
Paritzo et ,al. 2021 | UK | Healthcare Payer | US Dollars/2020 | Markov model | Life time | 3% |
Krittayaphong et al., 2020 | Thailand | Healthcare System | Thai Baht/2020 | Markov model | Life time | 3% |
Mendoza et al., 2021 | Philippines | Public Healthcare provider | Philippine Peso/2021 | Markov model | Life time | 3% |
Savira et al., 2020 | Australia | Australian Healthcare | Australian Dollars /2019 | Markov model | Life time | 5% |
Isaza et al., 2021 | US | US Healthcare Sector | US Dollars/2020 | Markov model | Life time | 3% |
McEwan et al., 2020 | UK, Germany, and Spain | Euro Multi-national Healthcare System | British Pound/2019 | Markov model | Life time | Spain and Germany: 3% |
Euro/2019 | UK: 3.5% | |||||
Yao et al., 2020 | China | Chinese Healthcare Payers | Chinese Renminbi/2020 | Markov model | 15 years | 4.2% |
Liao et al., 2021 | South Korea, Australia, Taiwan, Japan, and Singapore | Asia–Pacific Region Healthcare Systems | US Dollars/2020 | Markov model |   18 months | 3% |
  30 years | ||||||
Gil-Rojas, 2021 | Colombia | Colombian Health System | US Dollars/2020 | Markov model | Â Â 5 years in the base case | 5% |
  10 years in sensitivity analyses | ||||||
  16 years for the life expectancy analysis | ||||||
Jiang et al., 2021 | China | Chinese Medical and Health System | US Dollars/2021 | Markov model | Â Â 5Â years | 5% |
  10 years | ||||||
  15 years | ||||||
  20 years |